BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 23221565)

  • 1. 2G12-expressing B cell lines may aid in HIV carbohydrate vaccine design strategies.
    Doores KJ; Huber M; Le KM; Wang SK; Doyle-Cooper C; Cooper A; Pantophlet R; Wong CH; Nemazee D; Burton DR
    J Virol; 2013 Feb; 87(4):2234-41. PubMed ID: 23221565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody 2G12 recognizes di-mannose equivalently in domain- and nondomain-exchanged forms but only binds the HIV-1 glycan shield if domain exchanged.
    Doores KJ; Fulton Z; Huber M; Wilson IA; Burton DR
    J Virol; 2010 Oct; 84(20):10690-9. PubMed ID: 20702629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120.
    Astronomo RD; Lee HK; Scanlan CN; Pantophlet R; Huang CY; Wilson IA; Blixt O; Dwek RA; Wong CH; Burton DR
    J Virol; 2008 Jul; 82(13):6359-68. PubMed ID: 18434393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An engineered Saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies.
    Luallen RJ; Lin J; Fu H; Cai KK; Agrawal C; Mboudjeka I; Lee FH; Montefiori D; Smith DF; Doms RW; Geng Y
    J Virol; 2008 Jul; 82(13):6447-57. PubMed ID: 18434410
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.
    Calarese DA; Lee HK; Huang CY; Best MD; Astronomo RD; Stanfield RL; Katinger H; Burton DR; Wong CH; Wilson IA
    Proc Natl Acad Sci U S A; 2005 Sep; 102(38):13372-7. PubMed ID: 16174734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A yeast glycoprotein shows high-affinity binding to the broadly neutralizing human immunodeficiency virus antibody 2G12 and inhibits gp120 interactions with 2G12 and DC-SIGN.
    Luallen RJ; Fu H; Agrawal-Gamse C; Mboudjeka I; Huang W; Lee FH; Wang LX; Doms RW; Geng Y
    J Virol; 2009 May; 83(10):4861-70. PubMed ID: 19264785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression, glycoform characterization, and antibody-binding of HIV-1 V3 glycopeptide domain fused with human IgG1-Fc.
    Yang Q; Li C; Wei Y; Huang W; Wang LX
    Bioconjug Chem; 2010 May; 21(5):875-83. PubMed ID: 20369886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gold nanoparticles coated with oligomannosides of HIV-1 glycoprotein gp120 mimic the carbohydrate epitope of antibody 2G12.
    Marradi M; Di Gianvincenzo P; Enríquez-Navas PM; Martínez-Ávila OM; Chiodo F; Yuste E; Angulo J; Penadés S
    J Mol Biol; 2011 Jul; 410(5):798-810. PubMed ID: 21440555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polyepitope protein incorporated the HIV-1 mimotope recognized by monoclonal antibody 2G12.
    Karpenko LI; Scherbakova NS; Chikaev AN; Tumanova OY; Lebedev LR; Shalamova LA; Pyankova OG; Ryzhikov AB; Ilyichev AA
    Mol Immunol; 2012 Apr; 50(4):193-9. PubMed ID: 22341130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: implications for HIV-1 vaccine design.
    Wang LX; Ni J; Singh S; Li H
    Chem Biol; 2004 Jan; 11(1):127-34. PubMed ID: 15113002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1.
    Gach JS; Furtmüller PG; Quendler H; Messner P; Wagner R; Katinger H; Kunert R
    J Biol Chem; 2010 Jan; 285(2):1122-7. PubMed ID: 19903812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.
    Scanlan CN; Pantophlet R; Wormald MR; Ollmann Saphire E; Stanfield R; Wilson IA; Katinger H; Dwek RA; Rudd PM; Burton DR
    J Virol; 2002 Jul; 76(14):7306-21. PubMed ID: 12072529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bacterially expressed HIV-1 gp120 outer-domain fragment immunogens with improved stability and affinity for CD4-binding site neutralizing antibodies.
    Rathore U; Purwar M; Vignesh VS; Das R; Kumar AA; Bhattacharyya S; Arendt H; DeStefano J; Wilson A; Parks C; La Branche CC; Montefiori DC; Varadarajan R
    J Biol Chem; 2018 Sep; 293(39):15002-15020. PubMed ID: 30093409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Very few substitutions in a germ line antibody are required to initiate significant domain exchange.
    Huber M; Le KM; Doores KJ; Fulton Z; Stanfield RL; Wilson IA; Burton DR
    J Virol; 2010 Oct; 84(20):10700-7. PubMed ID: 20702640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polysaccharide mimicry of the epitope of the broadly neutralizing anti-HIV antibody, 2G12, induces enhanced antibody responses to self oligomannose glycans.
    Dunlop DC; Bonomelli C; Mansab F; Vasiljevic S; Doores KJ; Wormald MR; Palma AS; Feizi T; Harvey DJ; Dwek RA; Crispin M; Scanlan CN
    Glycobiology; 2010 Jul; 20(7):812-23. PubMed ID: 20181792
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV-1 envelope proteins and V1/V2 domain scaffolds with mannose-5 to improve the magnitude and quality of protective antibody responses to HIV-1.
    Morales JF; Morin TJ; Yu B; Tatsuno GP; O'Rourke SM; Theolis R; Mesa KA; Berman PW
    J Biol Chem; 2014 Jul; 289(30):20526-42. PubMed ID: 24872420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.
    Jardine JG; Ota T; Sok D; Pauthner M; Kulp DW; Kalyuzhniy O; Skog PD; Thinnes TC; Bhullar D; Briney B; Menis S; Jones M; Kubitz M; Spencer S; Adachi Y; Burton DR; Schief WR; Nemazee D
    Science; 2015 Jul; 349(6244):156-61. PubMed ID: 26089355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High temperature SELMA: evolution of DNA-supported oligomannose clusters which are tightly recognized by HIV bnAb 2G12.
    Temme JS; MacPherson IS; DeCourcey JF; Krauss IJ
    J Am Chem Soc; 2014 Feb; 136(5):1726-9. PubMed ID: 24446826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dissecting the carbohydrate specificity of the anti-HIV-1 2G12 antibody by single-molecule force spectroscopy.
    Martines E; García I; Marradi M; Padro D; Penadés S
    Langmuir; 2012 Dec; 28(51):17726-32. PubMed ID: 23198686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yeast-elicited cross-reactive antibodies to HIV Env glycans efficiently neutralize virions expressing exclusively high-mannose N-linked glycans.
    Agrawal-Gamse C; Luallen RJ; Liu B; Fu H; Lee FH; Geng Y; Doms RW
    J Virol; 2011 Jan; 85(1):470-80. PubMed ID: 20962094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.